DOCSLIB.ORG

Public Health Policy and Legislation Instruments and Tools: an Updated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Public Health Policy and Legislation Instruments and Tools: an Updated Annex to the document “Public health policy and legislation instruments and tools: an updated review and proposal for further research” EPHO 1: Surveillance of population health and well-being Level: Lead global, Evaluation notes (monitoring and assessment reports; activity Legal Title of instrument or tool with hyperlink organiza- regional, reports; expected outputs; countries implementation; status tion national or transparency) local Legally http://www.who.int/ihr/IHR_Monitoring_Framework_Checklis International Health Regulations (2005) WHO Global binding t_and_Indicators.pdf Commission Delegated Regulation (EU) No 363/2012 of 23 February 2012 on the procedural rules for the recognition and withdrawal of recognition of monitoring organisations as provided European Legally Regional not available (n/a) for in Regulation (EU) No 995/2010 of the European Parliament Union (EU) binding and of the Council laying down the obligations of operators who place timber and timber products on the market Commission Implementing Decision 2012/112/EU of 17 February 2012 amending Annex E to Council Directive 92/65/EEC as regards Legally the model health certificates for animals from holdings and EU Regional n/a binding animals, semen, ova and embryos from approved bodies, institutes or centres Commission Decision 2008/896/EC of 20 November 2008 on Legally guidelines for the purpose of the risk-based animal health EU Regional n/a binding surveillance schemes provided for in Council Directive 2006/88/EC http://ecdc.europa.eu/en/publications/Publications/Forms/EC DC_DispForm.aspx?ID=916; Decision No 2119/98/EC of the European Parliament and of the http://ecdc.europa.eu/en/publications/surveillance_reports/C Council of 24 September 1988 setting up a network for the Legally EU Regional ommunicable-Disease-Threats-Report/Pages/Communicable- epidemiological surveillance and control of communicable diseases binding Disease-Threats-Report.aspx; in the Community http://ecdc.europa.eu/en/publications/Publications/Forms/EC DC_DispForm.aspx?ID=767 Commission Decision 2003/534/EC of 17 July 2003 amending Decision No 2119/98/EC of the European Parliament and of the Council and Decision 2000/96/EC as regards communicable Legally EU Regional n/a diseases listed in those decisions and amending Decision binding 2002/253/EC as regards the case definitions for communicable diseases 1 Commission Decision 2007/875/EC of 18 December 2007 amending Decision No 2119/98/EC of the European Parliament Legally EU Regional n/a and of the Council and Decision 2000/96/EC as regards binding communicable diseases listed in those decisions Commission Decision 2000/57/EC of 22 December 1999 on the early warning and response system for the prevention and control Legally EU Regional n/a of communicable diseases under Decision No 2119/98/EC of the binding European Parliament and of the Council Commission Decision 2008/351/EC of 28 April 2008 amending Decision 2000/57/EC as regards events to be reported within the Legally EU Regional n/a early warning and response system for the prevention and control binding of communicable diseases Commission Decision 2009/547/EC of 10 July 2009 amending Decision 2000/57/EC on early warning and response system for the Legally EU Regional n/a prevention and control of communicable diseases under Decision binding No 2119/98/EC of the European Parliament and of the Council COM(2009) 228 final – Report from the Commission to the Council and the European Parliament: operation of the Early Warning and Non- Response System (EWRS) of the Community Network for the EU Regional legally n/a epidemiological surveillance and control of communicable diseases binding during 2006 and 2007 (Decision 2000/57/EC) COM(2007) 121 final – Report from the Commission to the Council and the European Parliament: on the operation of the Early Non- Warning and Response Systems (EWRS) of the Community EU Regional legally n/a Network for the epidemiological surveillance and control of binding communicable diseases during years 2004 and 2005 (Decision 2000/57/EC) COM(2005) 104 final – Report from the Commission to the Council and the European Parliament: report on the operation of the Early Non- Warning and Response System of the community network for the EU Regional legally n/a epidemiological surveillance and control of communicable diseases binding (Decision 2000/57/EC) during 2002 and 2003 http://www.euro.who.int/__data/assets/pdf_file/0004/147712 Non- The Tashkent Declaration “The Move from Malaria Control to /RC61_edoc05.pdf; WHO Regional legally Elimination” in the WHO European Region (2005) http://www.euro.who.int/__data/assets/pdf_file/0008/98774/ binding E92012.pdf 2 http://ec.europa.eu/health/communicable_diseases/early_war Decision No 2119/98/EC of the European Parliament and of the ning/comm_legislation_en.htm; Council of 24 September 1998 setting up a network for the Legally http://ec.europa.eu/health/communicable_diseases/labs/proj EU Regional epidemiological surveillance and control of communicable diseases binding ects/index_en.htm; in the Community (on the network of epidemiological surveillance) http://ec.europa.eu/health/preparedness_response/generic_p reparedness/index_en.htm; http://www.ecdc.europa.eu/en/publications/publications/101 Decision No 2119/98/EC of the European Parliament and of the 1_sur_annual_epidemiological_report_on_communicable_dise Council of 24 September 1998 setting up a network for the Legally EU Regional ases_in_europe.pdf; epidemiological surveillance and control of communicable diseases binding http://ecdc.europa.eu/en/aboutus/Key%20Documents/08- in the Community (on the communicable diseases to be covered) 13_KD_Surveillance_of_CD.pdf EU/Europe an Centre http://ecdc.europa.eu/en/publications/Publications/101111_S Framework Action Plan to Fight Tuberculosis in the European for Disease Legally PR_Progressing_towards_TB_elimination.pdf; Regional Union Prevention binding http://ecdc.europa.eu/en/publications/Publications/0803_SPR and Control _TB_Action_plan.pdf (ECDC) Non- WHO/ECD http://ecdc.europa.eu/en/publications/publications/1203- Tuberculosis surveillance and monitoring in Europe Regional legally C annual-tb-report.pdf; binding Non- http://ecdc.europa.eu/en/publications/Publications/101111_S Tuberculosis Programme ECDC Regional legally PR_Progressing_towards_TB_elimination.pdf binding Non- n/a European Tuberculosis Surveillance Network ECDC Regional legally binding http://www.euro.who.int/__data/assets/pdf_file/0007/147832 WHO Consolidated Action Plan to Prevent and Combat Multidrug- and Non- /wd15E_TB_ActionPlan_111388.pdf&sa=U&ei=TDLPUIWNG6ia Regional Extensively Drug-Resistant Tuberculosis in the WHO European Regional legally 0QXqvYGABg&ved=0CBUQFjAA&usg=AFQjCNG_M3BNwq0sUD Office for Region 2011–2015 binding 2gB-YHDDbE5YIwzQ Europe WHO http://www.euro.who.int/en/what-we-do/health- Non- Regional topics/environment-and-health/Climate- Heat–health action plans Regional legally Office for change/activities/public-health-responses-to-weather- binding Europe extremes2 WHO Regional Committee resolution EUR/RC61/R3: Action Plan for Non- http://www.euro.who.int/__data/assets/pdf_file/0017/150614 Regional implementation of the European Strategy for the Prevention and Regional legally /RC61_Res_03.pdf Office for Control of Noncommunicable Diseases 2012–2016 binding Europe 3 WHO Non- Action plan for implementation of the European Strategy for the Regional http://www.euro.who.int/__data/assets/pdf_file/0009/164457 Regional legally Prevention and Control of Noncommunicable Diseases 2012–2016 Office for /e96502.pdf binding Europe http://www.euro.who.int/en/who-we-are/whd/past-themes- of-world-health-day/world-health-day-2011-antibiotic- WHO resistance-no-action-today,-no-cure-tomorrow/world-health- Non- Regional Committee working document EUR/RC61/14: European Regional day-2011/developing-a-national-surveillance-system-for- Regional legally strategic action plan on antibiotic resistance Office for antimicrobial-resistance; http://www.euro.who.int/en/where- binding Europe we-work/member- states/belarus/news/news/2012/06/assessing-antibiotic- resistance-in-belarus http://www.euro.who.int/en/what-we-do/health- topics/communicable-diseases/measles-and-rubella; WHO Non- http://www.euro.who.int/en/what-we-do/health- Eliminating measles and rubella and preventing congenital rubella Regional Regional legally topics/disease-prevention/vaccines-and- infection: WHO European Region strategic plan 2005–2010 Office for binding immunization/publications/2012/who-epidemiological-brief- Europe 24-measles-and-rubella-update,-afp-surveillance-review-in- kyrgyzstan; http://data.euro.who.int/cisid/ http://www.euro.who.int/en/what-we-publish/information- WHO for-the-media/sections/features/2012/health-planning-for- Non- Regional large-public- Health planning for large public events Regional legally Office for events&sa=U&ei=yTLPUMXtHIeO0AXmoIHQCA&ved=0CBUQFj binding Europe AA&usg=AFQjCNFP7NKQqEC-bT4TOdWAiz9L2_uXPQ http://ecdc.europa.eu/en/activities/surveillance/tessy/pages/t Non- essy.aspx&sa=U&ei=3zLPUMuQLYKd0QWKwIHIBQ&ved=0CBY The European Surveillance System (TESSy) ECDC Regional legally QFjAA&usg=AFQjCNED96rDCNunWM9UMZiwmcXaDuJuCA binding http://www.ecdc.europa.eu/en/activities/surveillance/strategi Non- es_principles/Pages/surveillance_strategy.aspx&sa=U&ei=8jLP Surveillance of Communicable Diseases in the European Union: a ECDC Regional legally UP_ZNqqn0QXdqYAI&ved=0CBYQFjAA&usg=AFQjCNFkUFdNLfR long-term strategy: 2008–2013 binding utyqZRzUEcSLxyhgpjQ
Load more

Recommended publications
  • PERF III MRP Reflection Paper Final
    PERF III Acquis Working Group Doc. Ref.: EMEA/PERF/Acq/281/03/en/Final This document sets out discussions held in the PERF III Acquis Group. It intends to facilitate preparation and implementation of the relevant EC legislation. The document is of an informal character only and does not bind the parties. Phasing-in EU procedures: MRP and referrals September 23, 2003 PERF Acquis Implementation Priority Action Area Reflection Paper Having regard to the • expected date of the Enlargement (1.5.2004), • need - to comply with the Acquis Communautaire and to ensure basic principles of medicinal products legislation, i.e. protecting public health and completing the single market, - not to jeopardise the functioning of EU marketing authorisation procedures and to prepare both Acceding Countries and existing Member States for the new situation after Enlargement, - to create a reasonable basis for future regulation, - to provide guidance to the industry and other stakeholders, • discussions within PERF II - Acquis Implementation Priority Area meetings and reflection papers arising from these discussions1, the following conclusions have been agreed. A. Dealing with applications for marketing authorisation pending in the Acceding Countries before the day of accession I. Legal situation and options possible as of the day of accession As discussed within PERF II, all applications received by the Competent Authorities of Acceding Countries (ACs) before the day of accession are considered national applications. As of the day of accession Articles 17 (2) and 18 of the Directive 2001/83 (Articles 21 (2) and 22 of Directive 2001/822) due to the broad wording apply to all pending applications irrespective of when the application was submitted.
    [Show full text]
  • Guidelines on Good Clinical Practice Specific to Advanced Therapy Medicinal Products ("Atmps")
    EUROPEAN COMMISSION Brussels, 10.10.2019 C(2019) 7140 final GUIDELINES on Good Clinical Practice specific to Advanced Therapy Medicinal Products (Text with EEA relevance) EN EN GUIDELINES on Good Clinical Practice specific to Advanced Therapy Medicinal Products (Text with EEA relevance) Table of contents 1. Introduction .................................................................................................. 2 1.1. Scope..................................................................................................................... 2 1.2. General context .......................................................................................................... 2 2. Clinical Trial Design ........................................................................................ 3 3. Non-clinical studies .......................................................................................... 5 4. Quality of the investigational ATMPs ..................................................................... 6 4.1. General considerations .................................................................................................. 6 4.2. Tissues and cells of human origin ...................................................................................... 6 4.3. Medical devices ......................................................................................................... 7 4.4. Reconstitution ........................................................................................................... 7 5. Safe conduct
    [Show full text]
  • Regulations for Human Application
    3b Regulations for Human Application I. Peñuelas (Pamplona) Clinical trials in the European Union (EU) are defined as “investigations in humans intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of investigational medicinal products (IMP), and/or to identify any adverse reactions to IMPs and/or to study absorption, distribution, metabolism and excretion of IMPs with the object of ascertaining their safety and/or efficacy”. Consequently, clinical trials can be considered an indispensable part of clinical research which, in turn, is essential to develop medicinal products, and to develop and improve medical diagnosis and treatment. The rules governing medicinal products in the European Union are complex, and they can be found in Eudralex, published by the Directorate General for Health and Consumers, and in some papers documents published by the European Medicines Agency (EMA). Volume 1 of Eudralex (1) “The rules governing medicinal products in the European Union” compiles the body of EU legislation in the pharmaceutical sector for medicinal products for human use, including the basic Directive 2001/83/EC (“Community code relating to medicinal products for human use”). Volume 10 (2) contains legislation and guidance documents specifically applying to clinical trials and is organized in 6 chapters, dealing with (I) Application and Application Form, (II) Monitoring and Pharmacovigilance (III) Quality of the IMP, (IV) Inspections, (V) Additional Information and (VI) Legislation. The current complex legal situation concerning clinical trials and radiopharmaceuticals has been summarized by the Drug Development Committee of the EANM (3), while a summary of the differences among the regulatory frameworks of different European countries has been recently been reviewed (4) A major challenge for clinical research in Europe has been set by the change of how clinical trials have to be conducted.
    [Show full text]
  • Regulation (EU) No 536/2014 on Clinical Trials for Medicinal Products
    27.5.2014 EN Official Journal of the European Union L 158/1 I (Legislative acts) REGULATIONS REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance) THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty on the Functioning of the European Union, and in particular Articles 114 and 168(4)(c) thereof, Having regard to the proposal from the European Commission, After transmission of the draft legislative act to the national parliaments, Having regard to the opinion of the European Economic and Social Committee (1), After consulting the Committee of the Regions, Acting in accordance with the ordinary legislative procedure (2), Whereas: (1) In a clinical trial the rights, safety, dignity and well-being of subjects should be protected and the data generated should be reliable and robust. The interests of the subjects should always take priority over all other interests. (2) In order to allow for independent control as to whether these principles are adhered to, a clinical trial should be subject to prior authorisation. (3) The existing definition of a clinical trial as contained in Directive 2001/20/EC of the European Parliament and of the Council (3) should be clarified. For that purpose, the concept of clinical trial should be more precisely defined by introducing the broader concept of ‘clinical study’ of which the clinical trial is a category. That category should be defined on the basis of specific criteria.
    [Show full text]
  • Pda-Comments-On-The-Revised-Chapter-7-Of-The-Eu-Gmp-Guide-On-Outsourced-Activities.Pdf
    PDA Europe gGmbH Adalbertstr. 9 16548 Glienicke/ Germany 28 February 2011 Tel: +49 (0)33056 2377-0 Fax: +49 (0)33056 2377-77 Senior Vice President Dr. Georg L. Roessling European Commission [email protected] Pharmaceuticals Unit, Brussels https://europe.pda.org/index.php [email protected] OFFICERS Chair: European Medicines Agency Maik Jornitz Compliance and Inspection, London Sartorius Stedim Biotech [email protected] Chair-Elect: Anders Vinther, PhD Genentech REF : EudraLex, Volume 4 Secretary: Good Manufacturing Practice Rebecca Devine, PhD Regulatory Consultant Medicinal Products for Human and Veterinary Use Revised EU GMP Chapter 7: Outsourced Activities Treasurer: Harold Baseman ValSource Immediate Past Chair: John Shabushnig, PhD Dear Colleagues: Pfizer President: PDA is pleased to provide comments on revised Chapter 7 of the EU GMP Richard M. Johnson Guide, released for consultation in November 2010. Our comments were prepared by an international group of expert volunteers with experience DIRECTORS Jette Christensen in GMP and regulatory affairs. They consist of two general comments, Novo Nordisk mentioned below, and specific technical comments attached in the EMA matrix format. Gabriele Gori Novartis Vaccines and Diagnostics Comment 1, Scope: As presently written the chapter appears to apply Zena Kaufman Abbott primarily to contract manufacturing activities with a few references to contract testing. The full scope of the chapter is unclear regarding which Steven Mendivil Amgen outsourcing activities are covered. Michael Sadowski Baxter Healthcare Recommendation: In the EMEA concept paper relating to this revision (October 2009), Junko Sasaki Dainippon Sumitomo examples of outsourced activities potentially covered by the chapter were provided in Section 2.
    [Show full text]
  • Guidance on the Management of Clinical Trials During the Covid-19 (Coronavirus) Pandemic
    GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC Version 4 04/02/2021 Key changes from v3 (27-04-2020): remote source data verification Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111 Office: F101 08/082 - Tel. direct line +32 229-83630 CONTENTS 1. INTRODUCTION ........................................................................................... 3 2. INITIATING NEW TRIALS .......................................................................... 4 3. CHANGES TO ONGOING TRIALS ............................................................. 4 4. SAFETY REPORTING .................................................................................. 6 5. RISK ASSESSMENT ..................................................................................... 6 6. COMMUNICATION WITH AUTHORITIES ............................................... 7 7. AGREEMENT WITH AND COMMUNICATION BETWEEN SPONSORS, TRIAL SITES AND TRIAL PARTICIPANTS .............................................. 9 8. CHANGES TO INFORMED CONSENT .................................................... 10 9. CHANGES IN THE DISTRIBUTION OF THE INVESTIGATIONAL MEDICINAL PRODUCTS ........................................................................... 11 10. CHANGES IN THE DISTRIBUTION OF IN VITRO DIAGNOSTIC AND MEDICAL DEVICES ................................................................................... 14 11. CHANGES TO MONITORING ..................................................................
    [Show full text]
  • EUROPEAN COMMISSION Brussels, Eudralex the Rules Governing
    EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064597 EudraLex The Rules Governing Medicinal Products in the European Union EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use Introduction Document History The first edition of the Guide was published, including an annex 1989 on the manufacture of sterile medicinal products. The second edition was published; implementing Commission January 1992 Directives 91/356 of 13 June 1991 and 91/412 of 23 July 1991 laying down the principles and guidelines on good manufacturing practice for medicinal products for human use as well as for veterinary medicinal products. The second edition also included 12 additional annexes. An update of legal references was made. In the meantime, the August 2004 guide is updated as needed on the website of the European Commission, several additional annexes added. Re-structuring of GMP guide, consisting of Part I for medicinal October 2005 products for human and veterinary use and Part II for active substances used as starting materials, implementing Directives 2004/27/EC and 2004/28/EC. The current guide includes 17 Annexes, the former Annex 18 being replaced. Update of the text and introduction of a new Part III December 2010 Introduction The pharmaceutical industry of the European Union maintains high standards of Quality Management in the development, manufacture and control of medicinal products. A system of marketing authorisations ensures that all medicinal products are assessed by a competent authority to ensure compliance with contemporary requirements of safety, quality and efficacy.
    [Show full text]
  • Production of Radiopharmaceuticals for Clinical and Research Uses
    Production of radiopharmaceuticals for clinical and research uses The European perspective Philip Elsinga UMC Groningen The Netherlands The Rules European players in (radio‐) pharmaceutical legislation National authorities European Union • National regulations EMA D.G. Health • Licencing (London) (Brussels) • Inspection Medicinal products: • National Pharmacopeia • Directives • Evaluation • Control laboratories • Regulations • Supervision Professional organisations • Pharmacovigilance Council of Europe • PIC/S GMP •EANM E.D.Q.M. (Strasbourg) •AIPES Marketing •European Authorisation •..... Pharmacopeia Quality •OMCL network European laws and rules Directives Must be transposed to be effective Regulations Are immediately enforceable Other rules Decisions of the Council Opinions Recommendations Regulatory documents of importance for Radiopharmaceuticals (RP) Directive 2001/20/EC “Clinical Trial Directive” Directive 2001/83/EG Qualified Person,... Directive 2003/94/EC GMP Directive 2004/27/EC API according to GMP Directive 2005/28/EC GCP / Authorization for IMP CHMP/SWP/28367/2007 First in human clinical trial guideline (EMEA) Regulation (EC) No 1394/2007 Advanced therapy regulation The current challenge for PET‐radiopharmaceutical development are pharmaceutical regulations, not radiation safety issues Eudralex The Rules Governing Medicinal Products in the European Union http://ec.europa.eu/health/index_en.htm Vol 1: Medicinal Products for Human Use Directives 2001/83/EC: Community code relating to medicinal products for human use
    [Show full text]
  • Module 01. Setting the Scene, Introduction to the EU Regulatory Network
    Setting the Scene: Introduction to the EU Regulatory Network The EU and the EU regulatory system for medicines 2nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Riccardo Luigetti on 8 March 2018 Principal International Affairs Officer An agency of the European Union The European Union (EU) The EU is an union of 28 independent sovereign Member States located in Europe Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom The European Economic Area (EEA) is formed of the 28 EU Member States plus Island, Liechtenstein and Norway 1 EU Regulatory System The EU – Key Facts Population: >500m GDP: ~€ 13tn Global sales of medicines: 27% Official languages: 24 2 EU Regulatory System More Key Facts The EU: • Has developed a single market* through a standardised system of laws that apply to all its Member States The same rules and procedures apply to all the 28 Member States (e.g. regarding authorisation and supervision of safety of medicines) Accession to the EU means a commitment to apply the “acquis communautaire” (the body of legislation and guidance) to ensure that all EU Member States operate to the same standard *The Single Market refers to the EU as one territory without any internal borders or other regulatory obstacles to the free movement of goods and services…. The EU single market is based on 4 fundamental freedoms: free movement of people, services, goods and capital (Treaty of Rome).
    [Show full text]
  • Annex 15: Qualification and Validation
    Ref. Ares(2015)1380025 - 30/03/2015 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Medicinal Products – Quality, Safety and Efficacy Brussels, 30 March 2015 EudraLex Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Annex 15: Qualification and Validation Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use. Status of the document: Revision Reasons for changes: Since Annex 15 was published in 2001 the manufacturing and regulatory environment has changed significantly and an update is required to this Annex to reflect this changed environment. This revision to Annex 15 takes into account changes to other sections of the EudraLex, Volume 4, Part I, relationship to Part II, Annex 11, ICH Q8, Q9, Q10 and Q11, QWP guidance on process validation, and changes in manufacturing technology. Deadline for coming into operation: 1 October 2015 Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111 Principle This Annex describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products and may also be used as supplementary optional guidance for active substances without introduction of additional requirements to EudraLex, Volume 4, Part II.
    [Show full text]
  • Official Journal C 95 of the European Union
    Official Journal C 95 of the European Union Volume 58 English edition Information and Notices 21 March 2015 Contents II Information INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES European Commission 2015/C 95/01 Guidelines of 19 March 2015 on principles of Good Distribution Practice of active substances for medicinal products for human use (1) ....................................................................................... 1 2015/C 95/02 Guidelines of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use (1) ................................ 10 2015/C 95/03 Non-opposition to a notified concentration (Case M.7275 — Novartis/GlaxoSmithKline Oncology Business) (1) ......................................................................................................................... 14 2015/C 95/04 Non-opposition to a notified concentration (Case M.7496 — Panasonic/Ficosa Inversion/Ficosa International) (1) ................................................................................................................... 14 2015/C 95/05 Information related to data on Member States’ trusted lists as notified under Commission Decision 2009/767/EC, as amended ..................................................................................................... 15 EN (1) Text with EEA relevance IV Notices NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES Council 2015/C 95/06 Notice for
    [Show full text]
  • Pt Chapter 5 Production European Commission Health and Consumers Directorate-General
    PT CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Medicinal products – quality, safety and efficacy Brussels, <date> EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part 1 Chapter 3: Premises and Equipment Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use. Status of the document: Revision. Reasons for changes: The only change is to section 6 as part of the improved guidance on prevention of cross-contamination involving also Chapter 5 and includes reference to a new complementary toxicological assessment guidance. Deadline for coming into operation: <6 months from publication> Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel – Belgium. Telephone: (32-2) 299 11 11 ER 3 PREMISES AND EQUIPMENT Principle Premises and equipment must be located, designed, constructed, adapted and maintained to suit the operations to be carried out. Their layout and design must aim to minimise the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt and, in general, any adverse effect on the quality of products.
    [Show full text]